We are analyzing https://link.springer.com/article/10.1007/s00424-003-1146-4.

Title:
The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects | Pflügers Archiv - European Journal of Physiology
Description:
The solute carrier family 1 (SLC1) includes five high-affinity glutamate transporters, EAAC1, GLT-1, GLAST, EAAT4 and EAAT5 (SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7, respectively) as well as the two neutral amino acid transporters, ASCT1 and ASCT2 (SLC1A4 and ALC1A5, respectively). Although each of these transporters have similar predicted structures, they exhibit distinct functional properties which are variations of a common transport mechanism. The high-affinity glutamate transporters mediate transport of l-Glu, l-Asp and d-Asp, accompanied by the cotransport of 3 Na+ and 1 H+, and the countertransport of 1 K+, whereas ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr. The unique coupling of the glutamate transporters allows uphill transport of glutamate into cells against a concentration gradient. This feature plays a crucial role in protecting neurons against glutamate excitotoxicity in the central nervous system. During pathological conditions, such as brain ischemia (e.g. after a stroke), however, glutamate exit can occur due to “reversed glutamate transport”, which is caused by a reversal of the electrochemical gradients of the coupling ions. Selective inhibition of the neuronal glutamate transporter EAAC1 (SLC1A1) may be of therapeutic interest to block glutamate release from neurons during ischemia. On the other hand, upregulation of the glial glutamate transporter GLT1 (SLC1A2) may help protect motor neurons in patients with amyotrophic lateral sclerosis (ALS), since loss of function of GLT1 has been associated with the pathogenesis of certain forms of ALS.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Social Networks

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure if the website is profiting.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

google, scholar, cas, pubmed, glutamate, transporter, article, amino, acid, transporters, transport, hediger, brain, glt, expression, neurosci, kanai, eaat, neutral, neuronal, excitatory, rothstein, kavanaugh, biol, cell, highaffinity, chem, rat, glial, amyotrophic, lateral, sclerosis, usa, human, sci, neuron, nature, slca, proc, natl, acad, eaac, nadependent, kanner, glast, protein, amara, mice, uptake, family,

Topics {✒️}

excitatory amino-acid transporter dependent glutamate/aspartate transporter concentration gradient month download article/chapter high-affinity glutamate transporter high-affinity glutamate transporters transcription factor nf-kappab gaba high-affinity uptake oxidative stress-induced impairment amino acid transporters rat brainl-glutamate transporter mammalian na+/glutamate cotransporters noise-induced hearing loss amyotrophic lateral sclerosis neuron-related regulatory mechanisms sodium/l-glutamate cotransport substrate-gated anion conductance excitatory amino acids glutamate transporter eaat2 ligand-gated chloride channel glial glutamate transporter human glutamate transporter glial glutamate transporters related subjects extracellular accessibility cell surface expression glutamate transporter expression glutamate transporter glt-1 neuronal glutamate transporter full article pdf cultured hippocampal cells glutamate transporters reveals electrochemical gradients brain glutamate transporters glutamate transporter glast glutamate transporters glast growth hormone overexpressing glial cell processes privacy choices/manage cookies �reversed glutamate transport” pentylenetetrazole-induced seizures neuronal transporters relevant human glioma cells abnormal eaat2 transcripts electrogenicl-glutamate uptake glutamate uptake produces excitatory synaptic currents retinal glutamate homeostasis brown rh jr tissue specific variants

Questions {❓}

Pow DV, Barnett NL, Penfold P (2000) Are neuronal transporters relevant in retinal glutamate homeostasis?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects
         description:The solute carrier family 1 (SLC1) includes five high-affinity glutamate transporters, EAAC1, GLT-1, GLAST, EAAT4 and EAAT5 (SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7, respectively) as well as the two neutral amino acid transporters, ASCT1 and ASCT2 (SLC1A4 and ALC1A5, respectively). Although each of these transporters have similar predicted structures, they exhibit distinct functional properties which are variations of a common transport mechanism. The high-affinity glutamate transporters mediate transport of l-Glu, l-Asp and d-Asp, accompanied by the cotransport of 3 Na+ and 1 H+, and the countertransport of 1 K+, whereas ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr. The unique coupling of the glutamate transporters allows uphill transport of glutamate into cells against a concentration gradient. This feature plays a crucial role in protecting neurons against glutamate excitotoxicity in the central nervous system. During pathological conditions, such as brain ischemia (e.g. after a stroke), however, glutamate exit can occur due to “reversed glutamate transport”, which is caused by a reversal of the electrochemical gradients of the coupling ions. Selective inhibition of the neuronal glutamate transporter EAAC1 (SLC1A1) may be of therapeutic interest to block glutamate release from neurons during ischemia. On the other hand, upregulation of the glial glutamate transporter GLT1 (SLC1A2) may help protect motor neurons in patients with amyotrophic lateral sclerosis (ALS), since loss of function of GLT1 has been associated with the pathogenesis of certain forms of ALS.
         datePublished:2003-10-07T00:00:00Z
         dateModified:2003-10-07T00:00:00Z
         pageStart:469
         pageEnd:479
         sameAs:https://doi.org/10.1007/s00424-003-1146-4
         keywords:
            Amyotrophic Lateral Sclerosis
            Glutamate Transporter
            Neutral Amino Acid Transporter
            Extracellular Glutamate Concentration
            Electrochemical Potential Gradient
            Human Physiology
            Molecular Medicine
            Neurosciences
            Cell Biology
            Receptors
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flb1.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4fhb2.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc3.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc4.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc5.gif
         isPartOf:
            name:Pflügers Archiv
            issn:
               1432-2013
               0031-6768
            volumeNumber:447
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yoshikatsu Kanai
               affiliation:
                     name:Kyorin University School of Medicine
                     address:
                        name:Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthias A. Hediger
               affiliation:
                     name:Harvard Medical School
                     address:
                        name:Membrane Biology Program, Renal Division, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects
      description:The solute carrier family 1 (SLC1) includes five high-affinity glutamate transporters, EAAC1, GLT-1, GLAST, EAAT4 and EAAT5 (SLC1A1, SLC1A2, SLC1A3, SLC1A6, and SLC1A7, respectively) as well as the two neutral amino acid transporters, ASCT1 and ASCT2 (SLC1A4 and ALC1A5, respectively). Although each of these transporters have similar predicted structures, they exhibit distinct functional properties which are variations of a common transport mechanism. The high-affinity glutamate transporters mediate transport of l-Glu, l-Asp and d-Asp, accompanied by the cotransport of 3 Na+ and 1 H+, and the countertransport of 1 K+, whereas ASC transporters mediate Na+-dependent exchange of small neutral amino acids such as Ala, Ser, Cys and Thr. The unique coupling of the glutamate transporters allows uphill transport of glutamate into cells against a concentration gradient. This feature plays a crucial role in protecting neurons against glutamate excitotoxicity in the central nervous system. During pathological conditions, such as brain ischemia (e.g. after a stroke), however, glutamate exit can occur due to “reversed glutamate transport”, which is caused by a reversal of the electrochemical gradients of the coupling ions. Selective inhibition of the neuronal glutamate transporter EAAC1 (SLC1A1) may be of therapeutic interest to block glutamate release from neurons during ischemia. On the other hand, upregulation of the glial glutamate transporter GLT1 (SLC1A2) may help protect motor neurons in patients with amyotrophic lateral sclerosis (ALS), since loss of function of GLT1 has been associated with the pathogenesis of certain forms of ALS.
      datePublished:2003-10-07T00:00:00Z
      dateModified:2003-10-07T00:00:00Z
      pageStart:469
      pageEnd:479
      sameAs:https://doi.org/10.1007/s00424-003-1146-4
      keywords:
         Amyotrophic Lateral Sclerosis
         Glutamate Transporter
         Neutral Amino Acid Transporter
         Extracellular Glutamate Concentration
         Electrochemical Potential Gradient
         Human Physiology
         Molecular Medicine
         Neurosciences
         Cell Biology
         Receptors
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flb1.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4fhb2.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc3.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc4.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00424-003-1146-4/MediaObjects/s00424-003-1146-4flc5.gif
      isPartOf:
         name:Pflügers Archiv
         issn:
            1432-2013
            0031-6768
         volumeNumber:447
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yoshikatsu Kanai
            affiliation:
                  name:Kyorin University School of Medicine
                  address:
                     name:Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthias A. Hediger
            affiliation:
                  name:Harvard Medical School
                  address:
                     name:Membrane Biology Program, Renal Division, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pflügers Archiv
      issn:
         1432-2013
         0031-6768
      volumeNumber:447
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Kyorin University School of Medicine
      address:
         name:Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan
         type:PostalAddress
      name:Harvard Medical School
      address:
         name:Membrane Biology Program, Renal Division, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yoshikatsu Kanai
      affiliation:
            name:Kyorin University School of Medicine
            address:
               name:Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan
               type:PostalAddress
            type:Organization
      name:Matthias A. Hediger
      affiliation:
            name:Harvard Medical School
            address:
               name:Membrane Biology Program, Renal Division, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Pharmacology and Toxicology, Kyorin University School of Medicine, Tokyo, Japan
      name:Membrane Biology Program, Renal Division, Brigham and Women’s Hospital, Harvard Institutes of Medicine, Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(227)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.16s.

LINK . SPRINGER . COM {}